Abstract
Efficacy of Subcutaneous Tocilizumab for the Treatment of Refractory Large Vessel Vasculitis in a Patient with Latent Tuberculosis Infection
Highlights
TCZ, administered in monthly i.v. infusions, is efficacious for the treatment of refractory large-vessel vasculitis in which it may control symptoms and C-reactive protein (CRP) [1,2,3,4,5]
CST are the treatment of choice of large-vessel vasculitis, which may relapse when dosages are tapered or suspended; different strategies have been proposed for the treatment of refractory large-vessel vasculitis, among which the introduction of immunosuppressive and cytotoxic drugs (MTX, azatioprine, cyclophosphamide) or anti TNF-α [1,2,3,4,5]
TCZ, a strong IL-6 inhibitor, has been efficaciously employed for the treatment of refractory large-vessel vasculitis, in which it showed to be effective in obtaining the disease remission, with amelioration of clinical manifestations and control of acute-phase reactants; TCZ has been employed mostly in combination with MTX but there are no guidelines about which of the two drugs should be left to mantain the remission [6,10,11,12,13,14,15]
Summary
TCZ, administered in monthly i.v. infusions, is efficacious for the treatment of refractory large-vessel vasculitis in which it may control symptoms and C-reactive protein (CRP) [1,2,3,4,5]. We confirm the efficacy and safety of TCZ in a patient affected by refractory disease, if administered in weekly s.c. injections.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
